Endocyte (ECYT)

Create an Alert
12.88 +0.18  +1.42%   NASDAQ Jun 18, 8:00PM BATS Real time Currency in USD

Endocyte R&D Expense Quarterly:

12.26M for March 31, 2013
View Full Chart

Endocyte R&D Expense Quarterly Chart

    Endocyte Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 12.26M
    Dec. 31, 2012 10.52M
    Sept. 30, 2012 9.931M
    June 30, 2012 8.806M
    March 31, 2012 6.417M
    Dec. 31, 2011 7.752M
    Sept. 30, 2011 8.916M
    June 30, 2011 7.722M
       
    March 31, 2011 4.438M
    Dec. 31, 2010 3.290M
    Sept. 30, 2010 3.672M
    June 30, 2010 3.70M
    March 31, 2010 3.899M
    Dec. 31, 2009 4.123M
    Sept. 30, 2009 3.806M

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    ECYT R&D Expense Quarterly Benchmarks

    Companies
    TrovaGene 0.5941M
    AEterna Zentaris 4.401M
    Ariad Pharmaceuticals 41.26M

    ECYT R&D Expense Quarterly Rankings

    Overall 95th percentile
    717 of 16773
    Sector 87th percentile
    183 of 1408 in Healthcare
    Industry 84th percentile
    68 of 453 in Biotechnology

    ECYT R&D Expense Quarterly Range, Past 5 Years

    Minimum 3.290M Dec 2010
    Maximum 12.26M Mar 2013
    Average 6.616M

    Access watchlists and custom data alerts.
    Start your free account.

    Registering enables you to view unlimited pages per month.

    required
    required
    required
    required
    Get Started Now

    Already registered? Sign in here.

    document.write('');